Showing 5 posts of 5 posts found.


Takeda’s Adcetris secures expanded approval in Europe for untreated CD30+ Stage IV Hodgkin lymphoma

February 14, 2019
Sales and Marketing Adcetris, Cancer, Europe, Hodgkin lymphoma, Takeda, pharma

Takeda’s Adcetris (brentuximab vedotin) has seen its marketing authorisation expanded by the European Commission to include the treatment of previously …


Old CDF drug not recommended in initial NICE guidance due to lack of evidence

August 10, 2016
Research and Development, Sales and Marketing Adcetris, Cancer Drugs Fund, NICE, Takeda, hodgkin's lymphoma

The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Takeda’s Adectris (brentuximab vedotin), despite …


Phase III success for Takeda in lymphoma drug

August 1, 2016
Manufacturing and Production, Research and Development Adcetris, Seattle Genetics, Takeda, lymphoma

Takeda Oncology and Seattle Generic have announced new Phase III data for trial drug, Adcetris (brentuximab vedotin), in patients with …

Takeda image

Takeda eyes new drug licences following positive blood cancer studies

December 11, 2014
Research and Development, Sales and Marketing Adcetris, Takeda, Velcade, ash, bortezomib, brentuximab vedotin, hematology

Takeda is bringing its biotech arm in-house to create a global oncology business unit, which it says will drive forward …

Blood cancer drug Adcetris approved by FDA

August 24, 2011
Sales and Marketing Adcetris, Cancer, Seattle Genetics, lymphoma

The FDA has approved Seattle Genetics’ blood cancer drug Adcetris for two forms of lymphoma. Adcetris (brentuximab vedotin) can now …

Latest content